Secondary hypertension: The ways of management

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 753-768

  Rossi, Gian Paolo ^a   Seccia, Teresa M ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aldosterone; Angiotensin; Catecholamines; Hypertension; Renin; Renovascular

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CATECHOLAMINE; CHROMOGRANIN A; CLONIDINE; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLUCOCORTICOID; METADRENALIN; MINERALOCORTICOID; NORMETADRENALIN; POTASSIUM; REACTIVE OXYGEN METABOLITE; SARTAN DERIVATIVE;

ADENOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE PRODUCING ADENOMA; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DRUG EXPOSURE; FALSE POSITIVE RESULT; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOVOLEMIA; LABORATORY TEST; METABOLITE; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROBABILITY; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SALT LOADING; SCREENING; SENSITIVITY AND SPECIFICITY; TACHYCARDIA; TREATMENT INDICATION; TUMOR LOCALIZATION; URINE LEVEL; VON HIPPEL LINDAU DISEASE;

EID: 78649387923     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563843     Document Type: Article

References (90)

1. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007; 44: 1-85
2. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554-556
3. Laugesen LP, Hansen AG, Jensen H, Petersen A, Tonnesen KH. The prevalence of secondary hypertension in elderly hypertensive patients. Acta Med Scand Suppl 1983; 676: 161-177
4. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202
5. Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of diagnostic tests and procedures: principles and applications. Ann Intern Med 1981; 94: 557-592
6. Seccia TM, Rossi GP. Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. Crit Rev Clin Lab Sci 2005; 42: 393-452
7. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19: 88-90
8. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104-107
9. Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51: 1366-1371
10. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep 2004; 6: 1-4
11. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318
12. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298
13. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
14. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
15. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005; 12: 149-159
16. Katayama Y, Takata N, Tamura T, et al. A case of primary aldosteronism due to unilateral adrenal hyperplasia. Hypertens Res 2005; 28: 379-384
17. Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713-723
18. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism: part II: subtype differentiation and treatment. J Nephrol 2008; 21: 455-462
19. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-484
20. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16: 86-91
21. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489-2494
22. Rossi GP, Seccia TM, Palumbo G, et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension 2010; 55: 83-89
23. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 1997; 82: 457-460
24. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
25. Iwaoka T, Umeda T, Naomi S, et al. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension. Am J Hypertens 1993; 6: 899-906
26. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21: 995-1012
27. Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004; 15: 271-276
28. Rossi GP, Chiesura-Corona M, Tregnaghi A, et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993; 7: 357-363
29. Magill SB, Raff H, Shaker JL, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86: 1066-1071
30. Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002; 15: 459-464
31. Lumachi F, Marzola MC, Zucchetta P, et al. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun 2003; 24: 683-688
32. Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083-1090
33. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25 (Suppl 1): S143-S158
34. Miotto D, De Toni R, Pitter G, et al. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 2009; 54: 885-889
35. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-1235
36. Young WF, Jr., Stanson AW, Grant CS, Thompson GB, Van Heerden JA. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913-919
37. Seccia TM, Miotto D, De Toni R, et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 2009; 53: 761-766
38. Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22year single center experience. J Clin Endocrinol Metab 2009; 94: 2437-2445
39. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539-553
40. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983; 58: 802-804
41. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 1986; 220: 225-232
42. Kudva YC, Sawka AM, Young WF, Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533-4539
43. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
44. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648-652
45. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477-84
46. Montemurro D, Rossi GP. Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma. J Endocrinol Invest 2006; 29: 650-652
47. Zanin L, Rossi G, Poletti A, Piotto A, Chiesura-Corona M, Pessina AC. Necrosis of a phaeochromocytoma associated with spontaneous remission of diabetes and hypertension. Clin Endocrinol (Oxf) 1993; 39: 613-617
48. Massart PE, Hodeige D, Donckier J. Adrenomedullin: view on a novel vasodilatory peptide with natriuretic properties. Acta Cardiol 1996; 51: 259-269
49. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33-45
50. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298-1303
51. Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531-1538
52. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62: 377-411
53. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434
54. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984; 311: 764-770
55. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptideproducing endocrine neoplasms. N Engl J Med 1986; 314: 1145-1151
56. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 1990; 88: 607-613
57. Canale MP, Bravo EL. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994; 78: 1139-1144
58. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675
59. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23: 271-283
60. Neumann HP, Eng C, Mulligan LM, et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 1995; 274: 1149-1151
61. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851
62. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357: 1181-1182
63. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in non-syndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466
64. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294: 2057-2063
65. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC. Corticalsparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120: 1064-70
66. deS SP, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995; 96: 2503-2509
67. Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41: 687-696
68. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet 1994; 344: 237-239
69. Helin KH, Tikkanen I, von Knorring JE, et al. Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529
70. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a metaanalysis. Ann Intern Med 2001; 135: 401-411
71. Rossi GP, Pavan E, Chiesura-Corona M, et al. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci (Lond) 1997; 93: 435-443
72. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129: 705-711
73. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344: 431-442
74. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365-1377
75. Chiesura-Corona M, Feltrin GP, Savastano S, et al. Excess prevalence of supraaortic artery lesions in renovascular hypertension: an arteriographic study. Cardiovasc Intervent Radiol 1994; 17: 264-270
76. Rossi GP, Rossi A, Zanin L, et al. Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 1992; 5: 8-15
77. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2: 1608-1616
78. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 2002; 106: 1572-1585
79. de Leeuw PW. On the significance of renal vein renins in renovascular hypertension. J Hypertens 2002; 20: 843-845
80. Goldblatt H. Hypertension due to renal ischemia. Bull N Y Acad Med 1964; 40: 745-758
81. Glodny B, Glodny DE. John Loesch, discoverer of renovascular hypertension, and Harry Goldblatt: two great pioneers in circulation research. Ann Intern Med 2006; 144: 286-295
82. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17: 707-719
83. Case DB, Laragh JH. Reactive hyperreninemia in renovascular hypertension after angiotensin blockage with saralasin or converting enzyme inhibitor. Ann Intern Med 1979; 91: 153-160
84. Rossi G, Semplicini A, Pessina AC, et al. Dynamic evaluation of the renin-angiotensin system with captopril in screening for renovascular hypertension. G Ital Cardiol 1985; 15: 472-477
85. Muller FB, Sealey JE, Case DB, et al. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80: 633-644
86. Mann SJ, Pickering TG, Sos TA, et al. Captopril renography in the diagnosis of renal artery stenosis: accuracy and limitations. Am J Med 1991; 90: 30-40
87. Rossi GP, Zanin L, Dessi-Fulgheri P, et al. A renin-secreting tumour with severe hypertension and cardiovascular disease: a diagnostic and therapeutic challenge. Clin Exp Hypertens 1993; 15: 325-338
88. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410-417
89. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Annu Rev Med 2001; 52: 421-442
90. White CJ. Kiss My Astral: One seriously flawed study of renal stenting after another. Catheter Cardiovasc Intervent 2010; 75: 305-307.